Welcome to Multibagg AI
Log in to access personalized features
Dashboard
Portfolio
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
Investor Presentation
Q4 FY25
Investor Presentation
Q3 FY23
Investor Presentation
Q4 FY19
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Bearish
6
Neutral
4
Bullish
4
Bearish
6
Neutral
4
Bullish
36
Bearish
0
Neutral
0
Bullish
32
Discovery themes featuring this stock
Fredun Pharmaceuticals Limited is an Indian diversified pharmaceutical company that develops, manufactures and markets generics, OTC, dermaceutics, nutraceuticals, pet-care products and mobility aids, operating both in-house plants and a network of contract manufacturing partners while supplying finished formulations to multiple international markets.
Q3 FY26 total income rose to INR160.92 crore (+57% YoY) and 9M FY26 revenue reached INR426 crore (+48% YoY); EBITDA margins expanded meaningfully to ~15–16% with Q3 EBITDA of INR26.34 crore and net profit nearly doubling, reflecting simultaneous top-line growth and operational margin improvement across Fredun Pharmaceuticals' portfolio.
The company is rapidly scaling its new-age verticals — pet care, mobility, dermaceutics and nutraceuticals — with management targeting roughly 51% revenue from new-age business by 2029, backed by product launches, a pet-focused acquisition and targeted state-by-state rollouts that are delivering higher gross margins for Fredun Pharmaceuticals.
Fredun Pharmaceuticals completed a QIP recently and cites the proceeds alongside improved internal cash flows to meet working capital; finance costs rose in the short term due to bank changes and machinery loans, but management expects the elevated finance cost to moderate over the next few quarters as QIP liquidity is deployed.
Operations combine owned plants (clusters of 3–4) and an asset-light CMO network of ~37 partner facilities, plus recent automation investments; seasonality persists with March quarter typically stronger, while mobility and pet volumetric products require different distribution and stocking strategies that Fredun Pharmaceuticals is scaling across states.
Pharmaceuticals & Biotechnology
Pharmaceuticals
1,014 Cr
Low Risk
28.1
32.3
0.3
4.0
1,999.00
646.30
Sales CAGR
Profit CAGR
ROE
ROCE
Discovery themes featuring this stock
Fredun Pharmaceuticals Ltd (FREDUN) is currently trading at 1,839.15 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Fredun Pharmaceuticals Limited is an Indian diversified pharmaceutical company that develops, manufactures and markets generics, OTC, dermaceutics, nutraceuticals, pet-care products and mobility aids, operating both in-house plants and a network of contract manufacturing partners while supplying finished formulations to multiple international markets. Q3 FY26 total income rose to INR160.92 crore (+57% YoY) and 9M FY26 revenue reached INR426 crore (+48% YoY); EBITDA margins expanded meaningfully to ~15–16% with Q3 EBITDA of INR26.34 crore and net profit nearly doubling, reflecting simultaneous top-line growth and operational margin improvement across Fredun Pharmaceuticals' portfolio. The company is rapidly scaling its new-age verticals — pet care, mobility, dermaceutics and nutraceuticals — with management targeting roughly 51% revenue from new-age business by 2029, backed by product launches, a pet-focused acquisition and targeted state-by-state rollouts that are delivering higher gross margins for Fredun Pharmaceuticals. Fredun Pharmaceuticals completed a QIP recently and cites the proceeds alongside improved internal cash flows to meet working capital; finance costs rose in the short term due to bank changes and machinery loans, but management expects the elevated finance cost to moderate over the next few quarters as QIP liquidity is deployed. Operations combine owned plants (clusters of 3–4) and an asset-light CMO network of ~37 partner facilities, plus recent automation investments; seasonality persists with March quarter typically stronger, while mobility and pet volumetric products require different distribution and stocking strategies that Fredun Pharmaceuticals is scaling across states.
Over the past 52 weeks, Fredun Pharmaceuticals Ltd has traded between a low of ₹646.30 and a high of ₹1,999.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Fredun Pharmaceuticals Ltd has a market capitalization of approximately 1,013.87. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Fredun Pharmaceuticals Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 28.07 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 1,013.87 Cr, Fredun Pharmaceuticals Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Fredun Pharmaceuticals Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Fredun Pharmaceuticals Ltd is 28.07. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
315.70 | 1,175 Cr | 21.79 | 2.34 | 0.27 | 10.52 | 10.52 | 5.94 | ||
144.70 | 1,146 Cr | 6.08 | 0.84 | 0.00 | 2.27 | 1.19 | 16.09 | ||
409.35 | 1,040 Cr | 26.06 | 4.43 | 0.23 | 13.89 | 19.49 | 12.00 | ||
1820.00 | 1,014 Cr | 28.07 | 3.96 | 0.03 | 22.85 | 26.16 | 7.04 | ||
337.25 | 920 Cr | 11.23 | 2.35 | 0.79 | 28.46 | 27.38 | 13.04 | ||
230.40 | 905 Cr | 19.42 | 11.69 | 0.00 | 51.51 | 27.98 | 10.39 | ||
19.45 | 892 Cr | -9.97 | 1.76 | 0.43 | 12.11 | 12.71 | -8.73 | ||
| Median: 7 Co. | — | 315.70 | 1,014 Cr | 19.42 | 2.35 | 0.23 | 13.89 | 19.49 | 10.39 |
